Conor Cahill Email & Phone Number

Geneva, Switzerland

Brussels, Brussels Region, Belgium

Providing independent advice relating to development of products versus infectious diseases, especially vaccines.

Brussels

> Designed and implemented preclinical, clinical development and regulatory strategy for company’s infectious diseases targets. > Conceived and planned company’s in vivo policy, scope and practice. Responsible for in vivo research budget, forecasting and control. > Subject matter expert for product development for biologicals, focusing on vaccines against viral, parasitic and bacterial infectious diseases. > Oversaw and guided governance, nonclinical, clinical, regulatory and medical affairs strategy, policy and operations. > Represented company externally in science, development and policy discussions. Participated in board meetings.

Brussels

Univercells vaccines affiliate became Quantoom Biosciences in June 2021

Ghent

> Team and strategy leader for development of Argenx’ Vyvgart (subcutaneous). Focused on clinical and regulatory strategy targeting rapid licensure to fulfil unmet medical need and program management. > Member of working groups defining governance, finance and internal communications initiatives.

Leiden, Netherlands

> Led R&D teams responsible for development of vaccine candidates against Polio (Sabin IPV) and Zika.> Directed development strategy (manufacturing, early to mid-stage clinical development and regulatory), project management, risk analysis and mitigation. > Key point of contact for interactions with external stakeholders for funding, R&D and biocontainment (academic collaborators, industry partners in Europe and India, and supranational organizations including WHO, BMGF, NIH and BARDA). > Represented development teams at senior management meetings. Member of Janssen Vaccines R&D governance team.

Wavre, Belgium

> Advised on development strategy and partnerships relating to GSK’s inactivated polio vaccines/affordable pentavalent. Encompassed evaluation of opportunities for R&D collaborations in Asia, development of novel governance and compliance models for alliances/collaborations and supporting R&D efforts to provide affordable vaccination against polio and pertussis.

London, England Metropolitan Area

Wavre, Belgium

> Responsible for strategy and cross-departmental coordination of R&D supporting GSK’s polio vaccines portfolio with a focus on clinical development, regulatory and medical. Led life cycle management and new development activities. > Directed R&D activities for a joint venture to develop affordable novel paediatric vaccines. Focussed on manufacturing scale-up, preclinical research, early stage clinical development and finance. > Key contact with global polio eradication partners (WHO, BMGF). Accountable for corporate responsibility commitments for provision of oral polio vaccine for UNICEF.> Supervised project management and risk management. > Coordinated biocontainment for live polio viruses and led external outreach activities with other manufacturers and supranational agencies.

Wavre, Belgium

> Management of global medical activities relating to GSK’s tetanus/pertussis booster vaccines.> Prepared, reviewed and approved promotional and educational material and scientific publications. Phase IV study management and external scientific outreach.> Provided scientific expertise on portfolio for internal and external audiences.> Responsible for activities including congresses, educational meetings and advisory boards.

Wavre, Belgium

> Briefed regulators and authorities on GSK’s pandemic influenza portfolio and strategy; designed material for management meetings with external bodies. Expert advisor for regional GSK staff. > Responsible for planning, conduct and reporting of advisory boards, congresses, preparation and approval of promotional and scientific materials. Provided training to GSK medical staff worldwide. > Served as member of Issues Management Team, coordinating response of safety concerns.> Managed scientific outreach and discussions with key opinion leaders.

Wavre, Belgium

> Briefed regulators and authorities on GSK’s pandemic influenza portfolio and strategy; designed material for management meetings with external bodies. Expert advisor for regional GSK staff. > Responsible for planning, conduct and reporting of advisory boards, congresses, preparation and approval of promotional and scientific materials. Provided training to GSK medical staff worldwide. > Served as member of Issues Management Team, coordinating response of safety concerns.> Managed scientific outreach and discussions with key opinion leaders.

Worked on a wide range of health-related projects for public and private sector clients in Belgium, France, Ireland, the UK and USA.

Rixensart, Belgium

> Principal writer for GSK’s malaria vaccine program (Mosquirix), in particular leading on Phase II and III protocols, reports and consent documents.> Liaised with external partners including investigator’s institutions in USA, Europe and Africa, and funding bodies (PATH Malaria Vaccine Initiative). > Later, worked as writing team co-leader, managing in-house and freelance consultant writers. > Worked on governance teams designing standard document templates and SOPs relating to protocols, reports, informed consent and formatting.

London And Chiang Mai, Thailand

> Worked as a scientist and project coordinator for a multidisciplinary programme, based full time in Chiang Mai, Thailand

Master Of Public Health (Mph), Public Health

Pgdip (Postgraduate Diploma), Science Communication

Msc, Zoology

Ba (Mod), Natural Sciences/Zoology

Education record